Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CCA, ERP, FVT

Halozyme to Host Investor Business Forum and Long-Term Outlook Call


SAN DIEGO, Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, January 17, 2024 at 5:30 a.m. PT / 8:30 a.m. ET.

On the call, Dr. Helen Torley, President and Chief Executive Officer will be joined by Mark Snyder, Chief Legal Officer and Nicole LaBrosse, Chief Financial Officer to present detailed guidance around the patent dynamics that are expected to drive revenue durability of Halozyme's ENHANZE® drug delivery technology.  The company will also provide 2024 financial guidance as well as long term financial outlook.

A webcast of the live call can be accessed via link here: https://ow.ly/Zi0050QqaCF. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials related to the call, please visit Halozyme.com.

The conference call may also be accessed with the dial-in information below:
Participant Toll-Free Number: 800-225-9448
Participant Direct/International Number: 203-518-9708
Conference ID: HALO0117

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including Hylenex® and XYOSTED® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]  

Samantha Gaspar  
Teneo
617-877-9710
[email protected] 

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

 

SOURCE Halozyme Therapeutics, Inc.


These press releases may also interest you

at 08:51
On February 11, Energy 3000 Solar GmbH (hereinafter referred to as "Energy 3000"), a European distributor of PV products, officially signed a strategic cooperation agreement with LONGi Green Energy Technology Co., Ltd. (hereinafter referred to as...

at 08:50
XTM, ("XTM" or the "Company") (QB: XTMIF / CSE:PAID / FSE:7XT) a fintech company specializing in innovative payment solutions including Automated Tip Pooling Calculations and Pay-Outs, and Earned Wage Access ("EWA") through its AnyDaytm platform, is...

at 08:39
Online Labels Group is proud to announce the acquisition of LabelValue, a distinguished provider of blank and custom labels based in Tampa, Florida. This strategic expansion reinforces Online Labels Group's industry leadership, elevating its ability...

at 08:38
A Tiger Group online auction on February 25 features excess AV gear from Solotech. "Tiger Group is extremely pleased to have been selected by Solotech as the asset-disposition provider for its Southern California depot," said Jonathan Holiday,...

at 08:35
flyExclusive Inc. , a publicly traded provider of premium jet charter experiences, has entered a definitive agreement to acquire the aviation business of Jet.AI Inc. , an innovative private aviation and artificial intelligence company. flyExclusive...

at 08:35
Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder...



News published on and distributed by: